Clark Qun Pan

This inventor holds 56 USPTO granted patents and 26 published patent applications, plus 6 CIPO patents and 29 EPO patents, primarily in Glycoengineering Innovations. Top assignees: Genzyme Corporation, Bayer Pharmaceuticals Corporation, Bayer Healthcare LLC. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clark Qun Pan. Retrieved from https://idiyas.com/inventor/clark-qun-pan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 56 (Patent Applications = 26)

% Patents Active = 73.2

CIPO Patents = 6 (Patent Applications = 9)

EPO Patents = 29 (Patent Applications = 34)

Average Co-Inventor Count = 4.7

ph-index = 11

Forward Citations = 343(Granted Patents)

Forward Citations (Not Self Cited) = 268(Dec 10, 2025)

Location History:

Sudhury, MA (US) (2015)
Castro Valley, CA (US) (2005 - 2016)
Framingham, MA (US) (2016)
Cambridge, MA (US) (2017)
Bridgewater, NJ (US) (2017 - 2020)
Sutton, MA (US) (2017 - 2023)
Lexington, MA (US) (2023)
Sudbury, MA (US) (2010 - 2024)

Company Filing History:

Bayer Pharmaceuticals Corporation

Takeda Pharmaceutical Company Limited

Bayer Aktiengesellschaft

patents

8. 1 out of 77

Bayer Healthcare Aktiengesellschaft

Shire-Nps Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Glycoengineering

Antibody-Drug Conjugation

Peptide Analogs

Oligosaccharide-Protein Conjugates

Heme Oxygenase-1

Transforming Growth Factor

Hyperglycosylated Polypeptides

Fc Containing Polypeptides

Parathyroid Hormone Variants

VEGF Antagonist Compositions

Affinity Purification

Engineered Antibodies

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12674003 - SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES (2026-07-07),

2. 12616742 - Recombinant Heme Oxygenase-1 (HO-1) for the Treatment of Sickle Cell Disease (2026-05-05),

3. 12503498 - FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION (2025-12-23),

4. 12473356 - SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY (2025-11-18),

5. 12291556 - Parathyroid hormone variants (2025-05-06),

6. 12252504 - Oligosaccharide-protein conjugates (2025-03-18),

7. 12110338 - Site-specific antibody-drug conjugation through glycoengineering (2024-10-08),

8. 11976112 - scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity (2024-05-07),

9. 11807690 - Hyperglycosylated binding polypeptides (2023-11-07),

10. 11697690 - Site-specific glycoengineering of targeting moieties (2023-07-11),

11. 11685912 - Affinity purification of glycosidase-cleaving enzymes (2023-06-27),

12. 11660328 - GLP-2 analogs and peptibodies for administration before, during or after surgery (2023-05-30),

13. 11634468 - Parathyroid hormone variants (2023-04-25),

14. 11325971 - scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity (2022-05-10),

15. 11279725 - Oligosaccharide-protein conjugates (2022-03-22),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide information on inventor Clark Qun Pan for your article.

Title: Unveiling the Inventive Mind of Clark Qun Pan

Introduction:

Clark Qun Pan, a prolific inventor hailing from Cambridge, MA (US), has left an indelible mark on the field of biotechnology with his numerous patents and groundbreaking innovations.

Latest Patents:

With an impressive portfolio of 48 patents, Clark Qun Pan's latest inventions include "Hyperglycosylated Binding Polypeptides" and "Site-specific Glycoengineering of Targeting Moieties." These patents revolutionize the domain of antigen-binding polypeptides and glycan engineering.

Career Highlights:

Throughout his illustrious career, Clark Qun Pan has made significant contributions while working at renowned companies such as Genzyme Corporation and Bayer Pharmaceuticals Corporation. His expertise and dedication have propelled him to the forefront of cutting-edge research and development in the biopharmaceutical industry.

Collaborations:

Collaborating with esteemed coworkers like Huawei Qiu and James E Stefano, Clark Qun Pan has fostered a culture of innovation and excellence. Together, they have synergized their talents to enhance the efficacy and scope of their groundbreaking inventions.

Conclusion:

In conclusion, Clark Qun Pan stands as a shining example of ingenuity and perseverance in the realm of biotechnological innovations. His relentless pursuit of excellence and collaborative spirit continue to inspire and shape the landscape of modern biopharmaceutical research.

Profile summary based on public USPTO records.